Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

Original reporting
Published Nov 11, 2026, 3:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$LEGNBullishMed
01

Why it matters

Earnings beat expectations with strong sales and cash, likely supporting share price appreciation.

02

Market read

First disclosure of quarterly financials provides fresh data for traders.

03

What to watch

Potential regulatory or manufacturing bottlenecks for CAR‑T scale‑up.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Legend Biotech presented Q3 2026 results, focusing on CARVYKTI performance and pipeline updates.

Company-level read

Ticker impact

$LEGNBullishHigh confidence
Context

Q3 2026 earnings call disclosed CARVYKTI net trade sales of $710M (+36% YoY) and $853M cash balance.

Expected impact

likely upward pressure as market prices in robust revenue growth

Evidence & confidence

First report of quarterly sales and cash figures, material for valuation.

Market effects

Boosts outlook for cell‑therapy and biotech sector.

Positive for US biotech equities.

Highlights growth in CAR‑T therapies worldwide.

Counterpoint

High valuation multiples may limit upside despite sales growth.

Key entities

  • Legend Biotech

    US‑listed biotech developing CAR‑T therapies.

Related articles

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.

$LEGNHigh

Legend Biotech Corp (LEGN): Financial results for Q3 2026

Legend Biotech Corp (LEGN) furnished an SEC Form 6-K — earnings release. Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights • CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million • Half of CARTITUDE-2 Cohort A patients remained alive and progress